FDA Approves Gazyva for Idiopathic Nephrotic Syndrome in Patients Aged 2 and Older

Sep 29, 2026 - 04:00
 0  1
South San Francisco, CA — September 25th, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), has received U.S. Food and Drug Administration (FDA) approval of Gazyva (obinutuzumab) to reduce the risk of relapse in...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0